Eyeing The Future, QuVa Pharma Announces Successful Capital Raise

Company raises $41 million to support investments in 2019 capacity amid accelerating demand; cements itself as a national leader with near term path to 240,000 sq. ft. of production capacity — Sugar Land, TX – July 24, 2018 – QuVa Pharma, Inc. today announced it has raised additional debt funding of up to $41 million […]

QuVa Pharma in Training Program for First Responders in Terror Events

— Bloomsbury, NJ facility used for Special Operations “active shooter” exercise—    Sugar Land, TX – Mar 6, 2018 — QuVa Pharma, Inc. today announced that it has partnered with local law enforcement and special operations units to provide use of its Bloomsbury, New Jersey Facility to support the surrounding counties Special Operations First Responder Training […]

Amid Rapid Growth, QuVa Pharma Announces New Equity and Debt Funding

  – Company raises $40 million in new equity and debt to support capacity investments to meet accelerating demand for QuVa Pharma products; cements itself as an industry leader  – Sugar Land, TX – January 31, 2018 — QuVa Pharma, Inc. today announced it has raised additional debt and equity funding of up to $40 […]

QuVa Pharma Partners with WCCC on Job Opportunities

BLOOMSBURY (Jan. 24, 2018) – When QuVa Pharma started operations at its Northeast facility in July 2017 in Bloomsbury, officials wanted to make an impact on the regional community with jobs and other support efforts. It has done just that in six months. Arguably, the partnership between QuVa and Warren County Community College (WCCC) may have the most far-reaching […]

QuVa Pharma Announces Its Ability to Supply Hydromorphone and Morphine Pre-Filled Syringes

-Compounded Hydromorphone and Morphine syringes are expected to help alleviate drug shortages impacting the nation’s hospitals- There is a nation-wide shortage of pre-filled syringe presentations of hydromorphone and morphine. This shortage is expected to persist for a number of months. QuVa Pharma, Inc. is pleased to announce that it has available supplies of: Hydromorphone 1mg/ml […]

QuVa Pharma Announces FDA 503B Registration of its New Jersey Facility

Initial Phase of 160,000SF building redevelopment complete and facility to commence shipping product in September 2017 Sugar Land, TX – September 26th, 2017 – QuVa Pharma, Inc. a national supplier of sterile compounding services driving new quality standards in the industry, today announced it has received FDA registration as a 503B facility for its Bloomsbury, […]

Meet Stuart Hinchen of QuVa Pharma in Sugar Land

Meet Stuart Hinchen of QuVa Pharma in Sugar Land  

QuVa Pharma Operational Following Hurricane Harvey

Pleasingly I can report that as Friday is underway our QuVa operations are returning to normal.  The infrastructure across Houston is still very strained by flood waters, but the city itself is showing resilience as people are trying to get back to work.  Highways are impassable and secondary roads are jammed – some of our […]

QuVa Pharma Announces Licensure under California’s SBOP New 503B Outsource License Category

QuVa has commenced shipments to California hospitals including current drug shortage products Sugar Land, TX –July 5, 2017 – Following comprehensive cGMP audit of QuVa Pharma’s Sugar Land and Temple, Texas facilities, the California Board of Pharmacy has issued Outsource Facility licenses to both QuVa locations. The California Board of Pharmacy introduced this category of […]

QuVa Pharma Announces Availability of Sodium Bicarbonate Syringe

—Compounded Sodium Bicarbonate PF 8.4% 50mEq per syringe is expected to help alleviate chronic drug shortage impacting the nation’s hospitals— It has been widely reported in the national press, including US Today, Modern Healthcare, and the New York Times, that there is a nation-wide shortage of pharmaceutical quality sodium bicarbonate available to hospitals. A shortage […]